Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Cancer-Testis Antigen (CTA) and RNA-Splicing Target Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RBMY1C drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RBMY1C Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for eukaryotic post-translational modifications. |
View RBMY1C Products |
| Gene Delivery | RBMY1C Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and splicing functional assays. |
View RBMY1C Products |
| Benchmark Ab | Anti-RBMY1C Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View RBMY1C Products |
| Validator | RBMY1C siRNA Set For target knockdown verification in cellular functional assays. |
View RBMY1C Products |
| Related Target A | RBMX X-linked homolog. Crucial for off-target counter-screening to prevent systemic toxicity. |
View RBMX Products |
| Related Target B | RBMY1A1 Y-linked family member sharing high sequence homology. Essential for pan-RBMY selectivity profiling. |
View RBMY1A1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily counter-screening (RBMX vs. RBMY1C) | High-purity recombinant RBMX and RBMY1C proteins strictly verified by mass spectrometry. |
| Maintaining native phosphorylation states | HEK293 mammalian expression host ensures eukaryotic post-translational modifications. |
| Lack of reliable positive controls | Sequence-verified clinical benchmark antibodies available for assay baseline calibration. |
| False positives in RNA-binding assays | Validated RBMY1C siRNA included to confirm target-specific knock-down phenotypes. |
Live RBMY1C R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of RBMY1C (RNA Binding Motif Protein Y-Linked 1C) is gaining traction as oncology therapeutics expand into Cancer-Testis Antigens (CTAs) and RNA-splicing machinery. Because RBMY1C expression is physiologically restricted to the testes but aberrantly reactivated in hepatocellular carcinoma (HCC) and other male-specific malignancies, it presents an exceptional therapeutic window.
The race for RBMY1C therapeutics is intensifying, with major players shifting focus from traditional systemic chemotherapies to targeted small-molecule inhibitors of RNA-binding domains and immunotherapeutic modalities such as TCR-T and mRNA vaccines. As first-generation splicing modulators reach the clinic, the next wave of R&D is targeting RBMY1C selectivity to avoid off-target disruption of the essential, ubiquitously expressed X-linked homolog, RBMX.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Oncology-focused Biotechs | Hepatocellular Carcinoma (HCC) | Selectivity Assay (Need mutant vs. WT proteins, and RBMX counter-screening panels) |
| TCR-T / Immunotherapy | Cell Therapy Developers | Male-specific Solid Tumors | Antigen presentation validation (Need high-purity RBMY1C peptide/protein for MHC binding assays) |
| RNA Therapeutics (siRNA/ASO) | RNAi Specialists | Refractory Liver Cancers | Intracellular target knockdown validation (Need sequence-verified Lentivirus for stable cell line generation) |